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OBJECTIVES This study compared the effects of beta-blockade on transmural and spatial dispersion of
repolarization (TDR and SDR, respectively) between the LQT1 and LQT2 forms of
congenital long QT syndrome (LQTS).
BACKGROUND The LQT1 form is more sensitive to sympathetic stimulation and more responsive to
beta-blockers than either the LQT2 or LQT3 forms.
METHODS Eighty-seven-lead, body-surface electrocardiograms (ECGs) were recorded before and after
epinephrine infusion (0.1 g/kg body weight per min) in the absence and presence of oral
propranolol (0.5–2.0 mg/kg per day) in 11 LQT1 patients and 11 LQT2 patients. The
Q-Tend interval, the Q-Tpeak interval and the interval between Tpeak and Tend (Tp-e),
representing TDR, were measured and averaged from 87-lead ECGs and corrected by
Bazett’s method (corrected Q-Tend interval [cQTe], corrected Q-Tpeak interval [cQTp] and
corrected interval between Tpeak and Tend [cTp-e]). The dispersion of cQTe (cQTe-D) was
obtained among 87 leads and was defined as the interval between the maximum and
minimum values of cQTe.
RESULTS Propranolol in the absence of epinephrine significantly prolonged the mean cQTp value but
not the mean cQTe value, thus decreasing the mean cTp-e value in both LQT1 and LQT2
patients; the differences with propranolol were significantly larger in LQT1 than in LQT2
(p  0.05). The maximum cQTe, minimum cQTe and cQTe-D were not changed with
propranolol. Propranolol completely suppressed the influence of epinephrine in prolonging
the mean cQTe, maximum cQTe and minimum cQTe values, as well as increasing the mean
cTp-e and cQTe-D values in both groups.
CONCLUSIONS Beta-blockade under normal sympathetic tone produces a greater decrease in TDR in the
LQT1 form than in the LQT2 form, explaining the superior effectiveness of beta-blockers in
LQT1 versus LQT2. Beta-blockers also suppress the influence of sympathetic stimulation in
increasing TDR and SDR equally in LQT1 and LQT2 syndrome. (J Am Coll Cardiol
2002;39:1984–91) © 2002 by the American College of Cardiology Foundation
Genetic studies have shown that congenital long QT
syndrome (LQTS), a hereditary disorder characterized by a
prolonged QT interval and torsade de pointes (1–3), is
primarily an electrical disease caused by a mutation in
specific ion channel genes (4–6). Mutations in KCNQ1 and
KCNE1 are responsible for defects in the slowly activating
component of the delayed rectifier potassium current (IKs)
underlying the LQT1 and LQT5 forms of LQTS, whereas
mutations in KCNH2 and KCNE2 result in defects in the
rapidly activating component of the delayed rectifier potas-
sium current (IKr) responsible for the LQT2 and LQT6 (6).
Mutations in SCN5A decrease the function of the late
sodium channel (INa) responsible for LQT3. Recent clinical
and experimental studies have suggested that patients with
LQT1 syndrome are more sensitive to sympathetic stimu-
lation (physical or emotional stress) than are those with
either LQT2 or LQT3 syndrome (7–11). We recently used
87-lead, body-surface electrocardiography and reported that
epinephrine produced a greater increase in both transmural
and spatial dispersion of repolarization (TDR and SDR,
respectively), as well as the QT interval, in patients with
LQT1 than in those with LQT2 , which may explain why
those with LQT1 are more sensitive to sympathetic stimu-
lation (12). In contrast, beta-blockers have been reported to
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be most effective in suppressing cardiac events, such as
syncope or sudden cardiac death, in patients with LQT1 (7).
However, the mechanism responsible for the differential
effectiveness of beta-blockers between the LQT1 and
LQT2 syndromes is unclear. The peak and end of the
T-wave on the electrocardiogram (ECG) are reported to be
coincident with repolarization of epicardial and the longest
M-cell action potentials, respectively, so that the interval
between the Tpeak and Tend is expected to reflect TDR
(10,11,13–15). In this study, we recorded 87-lead, body-
surface mapping before and after epinephrine infusion in
the absence and presence of oral propranolol, a beta-blocker,
in patients with LQT1 or LQT2 syndrome, and we com-
pared the effects, in both the LQT1 and the LQT2
syndromes, of beta-blockade on TDR and SDR as well as
the QT interval, under normal sympathetic tone or during
sympathetic stimulation.
METHODS
Patient group. The study group included 11 patients with
LQT1 syndrome (KCNQ1 mutation; 6 unrelated families)
and 11 patients with LQT2 syndrome (KCNH2 mutation;
5 unrelated families). Six LQT1 families had six discrete
missense mutations, and 5 LQT2 families had five discrete
mutations. The LQT1 group consisted of eight females and
three males, ranging in age from 6 to 54 years (mean 30 16).
The LQT2 group included seven females and four males,
ranging in age from 17 to 61 years (mean 32  17 years).
87-lead, body-surface mapping. All protocols were re-
viewed and approved by our Ethical Review Committee,
and an informed consent was obtained from all patients. All
anti-arrhythmic medications, except oral propranolol, were
discontinued for at least five drug half-lives. Body-surface
potential mapping was recorded with the VCM-3000
(Fukuda Denshi Co., Tokyo, Japan) (16). Eighty-seven
body-surface leads were arranged in a lattice-like pattern
(13  7 matrix), except for four leads on the mid-axillary
lines, which covered the entire thoracic surface; 59 leads
were located on the anterior chest (rows A–I) and 28 leads
on the back (rows J–M). These 87 unipolar electrograms,
with Wilson’s central terminal as a reference, the standard
12-lead ECG and the Frank X, Y and Z scalar leads were
simultaneously recorded during sinus rhythm. All subjects
remained relaxed in the supine position during the record-
ing. The ECG data were scanned with multiplexers and
digitized using analog-to-digital converters with a sampling
rate of 1,000 samples/s per channel. The digitized data were
stored on a floppy disk and transferred to a personal
computer (PC-9821 Xv13 NEC, Tokyo, Japan); the anal-
ysis program was developed at our institution.
Measurements. Eighty-seven-lead, body-surface ECGs
were analyzed using a semi-automated digital program. The
Q-Tend interval (QTe) was defined as the time interval
between the QRS onset and the point at which the
isoelectric line intersected a tangential line drawn at the
minimum first derivative (dV/dt) point of the positive
T-wave or at the maximum dV/dt point of the negative
T-wave. When a bifurcated or secondary T-wave (patho-
logic U-wave) appeared, it was included as part of the
measurement of the QT interval, but a normal U-wave,
which was apparently separated from the T-wave, was not
included. The Q-Tpeak interval (QTp) was defined as the
time interval between the QRS onset and the point at the
peak of the positive T-wave or the nadir of the negative
T-wave. When a T-wave had a biphasic or notched con-
figuration, the peak of the T-wave was defined as that of the
dominant T-wave deflection. The QTe, QTp and interval
between the Tpeak and Tend (Tp-e) (QTe  QTp), as an
index of TDR, were measured automatically from all
87-lead ECGs, corrected to the heart rate by Bazett’s
method (corrected Q-Tend interval [cQTe], corrected
Q-Tpeak interval [cQTp] and corrected interval between
Tpeak and Tend [cTp-e]: QTe/RR, QTp/RR and Tp-e/
RR) and averaged among all 87 leads. Each point
determined by the computer was checked visually and edited
manually for each lead. The maximum and minimum values
of cQTe were also obtained from all 87 leads. As an index of
SDR, dispersion of the cQTe (cQTe-D) was obtained from
87 leads and defined as the interval between the maximum
and minimum values of the cQTe.
Epinephrine administration. A bolus injection of epi-
nephrine (0.1 g/kg body weight), an alpha- and beta-
adrenergic agonist, was immediately followed by continuous
infusion of epinephrine (0.1 g/kg per min), in the absence
and presence of oral propranolol administration (0.5–2.0
mg/kg per day, for at least 5 days or more) in both groups of
patients. Body-surface mapping was recorded during sinus
rhythm under baseline conditions and at steady-state condi-
tions of epinephrine (3–5 min after epinephrine infusion), in
which both the RR and QT intervals reached steady state.
Statistical analysis. Data are reported as the mean value 
SD. Two-way repeated-measures analysis of variance
(ANOVA), followed by the Scheffe´ F test, was used to
compare measurements made before and after drug admin-
istration and to compare each variable between the LQT1
and LQT2 groups. Differences in each variable before
and after drug administration were compared between the
two groups by using one-way ANOVA, followed by the
Scheffe´ F test. Differences in each variable before and after
epinephrine were also compared between the absence and
Abbreviations and Acronyms
APD  action potential duration
ECG  electrocardiogram
LQTS  long QT syndrome
cQTe  (corrected) Q-Tend interval
cQTp  (corrected) Q-Tpeak interval
cQTe-D  (corrected) dispersion of QTe
SDR  spatial dispersion of repolarization
cTp-e  (corrected) interval between Tpeak and Tend
TDR  transmural dispersion of repolarization
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Figure 1. Electrocardiographic lead I4 of the body-surface map, which corresponds to lead V6 of the standard 12-lead electrocardiogram, at the baseline
condition (A), with oral propranolol (B), during epinephrine infusion at baseline (C) and during epinephrine infusion with oral propranolol (D) in a patient
with LQT1 syndrome. Both cQTe and cQTp were prolonged (584 and 461 ms, respectievly) and cTp-e was increased (123 ms) at the baseline condition.
Propranolol produced no significant change in cQTe (588 ms), but prolonged cQTp (488 ms), resulting in a decrease in cTp-e (100 ms). Epinephrine
produced a remarkable prolongation in cQTe (710 ms), but a mild prolongation in cQTp (532 ms), resulting in an increase in cTp-e (178 ms), and this was
completely suppressed by oral propranolol. HR  heart rate.
Figure 2. Electrocardiographic lead I4 of the body-surface map, at the baseline condition (A), with oral propranolol (B), during epinephrine infusion at
baseline (C) and during epinephrine infusion with oral propranolol (D) in a patient with LQT2 syndrome. Both cQTe and cQTp were prolonged (545 and
429 ms, respectively) and cTp-e was increased (116 ms) at the baseline condition. Propranolol produced no significant change in cQTe (555 ms), but
prolonged cQTp (454 ms), resulting in a decrease in cTp-e (101 ms). Epinephrine produced a prolongation in cQTe (630 ms), but a mild prolongation in
cQTp (488 ms), resulting in an increase in cTp-e (142 ms), and this was completely suppressed by oral propranolol. HR  heart rate.
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presence of propranolol by using one-way ANOVA, fol-
lowed by the Scheffe´’s F test. A value of p  0.05 was
regarded as significant.
RESULTS
There were no significant differences in the heart rate
between the two groups before and after epinephrine in the
absence and presence of propranolol (epinephrine/
propranolol  /: 66  7 beats/min for LQT1 and 62 
5 beats/min for LQT2; /: 58  5 beats/min for LQT1
and 56  4 beats/min for LQT2; /: 76  6 beats/min
for LQT1 and 70  6 beats/min for LQT2; /: 50  5
beats/min for LQT1 and 50  4 beats/min for LQT2).
Effect of propranolol in the absence of epinephrine.
Figures 1A and 1B, illustrates ECG lead I4 of body-surface
mapping, which corresponds to lead V6 of the standard
12-lead ECG before and after propranolol in a patient with
LQT1 syndrome. Both the cQTe and cQTp were prolonged
(584 and 461 ms, respectively) and the cTp-e was increased
(123 ms) under the baseline condition. Propranolol pro-
duced no significant change in the cQTe (588 ms), but it did
prolong the cQTp (488 ms), resulting in a decrease in the
cTp-e (100 ms). Figures 2A and 2B, illustrates ECG lead I4
before and after propranolol in a patient with LQT2
syndrome. Propranolol also had no effect on the cQTe (545
3 555 ms), but it did prolong the cQTp (429 3 454 ms),
thus decreasing the cTp-e (116 3 101 ms). Changes in all
repolarization variable before and after propranolol in 11
LQT1 patients and 11 LQT2 patients are shown in Table
1. There were no significant differences in any baseline
variables between the LQT1 and LQT2 groups. In both
groups of patients, propranolol produced no significant
change in the mean cQTe value, but it did cause a significant
prolongation of the mean cQTp value, resulting in a
significant decrease in the mean cTp-e value. The differences
in the mean cQTp and mean cTp-e values with propranolol
were significantly larger in the LQT1 group than in the
LQT2 group (p 0.05) (Table 1). These findings were true
even though the repolarization variables were not corrected
by the heart rate. Figure 3 plots the mean QTe and mean
QTp values against the mean heart rate in the LQT1 and
LQT2 groups. In both groups, the mean Tp-e value (mean
QTe  mean QTp) after propranolol was smaller than that
under the baseline condition, even if the mean heart rate was
slower after propranolol. In contrast, no significant changes
were observed with propranolol in the maximum cQTe,
minimum cQTe and cQTe-D values in both groups of
patients (Table 1).
Effect of propranolol in the presence of epinephrine.
Figure 1C and Figure 2C illustrate ECG lead I4 of
body-surface mapping during epinephrine alone in patients
with LQT1 and LQT2 syndrome, respectively. In both
patient groups, epinephrine produced a prolongation of the
cQTe (710 and 630 ms in LQT1 and LQT2, respectively),
but a mild prolongation in the cQTp (532 and 488 ms, T
ab
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respectively), resulting in an increase in the cTp-e (178 and
142 ms, respectively). Changes in all repolarization variables
before and after epinephrine under the baseline condition in
11 LQT1 and 11 LQT2 patients are summarized in Table
2 and Figure 4. In both groups, epinephrine produced a
significant prolongation in the mean cQTe value, but not in
the mean cQTp value, resulting in a significant increase in
the mean cTp-e value. Moreover, epinephrine produced a
larger prolongation in the maximum cQTe than in the
minimum cQTe, resulting in a significant increase in the
cQTe-D in both groups. The differences in the mean cQTe,
mean cTp-e, maximum cQTe and cQTe-D values with
epinephrine were significantly larger in the LQT1 group
than in the LQT2 group (p 0.05) (Table 2, Figs. 4A, 4C,
4D and 4F). Once again, these findings were true even
though the mean QTe, mean QTp and mean Tp-e values
were not corrected by the heart rate (Fig. 3). In both groups,
the mean Tp-e value after epinephrine administration was
much greater than that under the baseline condition, even if
the mean heart rate was faster after epinephrine. Moreover,
the mean Tp-e value after epinephrine administration was
larger in the LQT1 group than in the LQT2 group, even if
the mean heart rate was faster in the LQT1 group.
Figures 1D and 2D illustrate ECG lead I4 of body-
surface mapping during epinephrine with oral propranolol
in patients with LQT1 and LQT2 syndrome, respectively.
Changes in all repolarization variables before and after
epinephrine with oral propranolol in 10 LQT1 and 9 LQT2
patients are summarized in Table 3 and Figure 4. In both
groups of patients, propranolol completely suppressed the
Figure 3. Plots of the mean QTe and mean QTp values against the mean
heart rate in 11 patients with LQT1 (open circles and squares) and 11
patients with LQT2 (solid circles and squares). In both groups of
patients, the mean Tp-e value (mean QTe  mean QTp) after propranolol
administration (P) was smaller than that at the baseline condition (B), even
if the mean heart rate was slower after propranolol. The mean Tp-e value
after epinephrine administration (E) was much greater than that at the
baseline condition, even if the mean heart rate was faster after epinephrine
in both groups. Moreover, the mean Tp-e value after epinephrine was larger
in the LQT1 group than in the LQT2 group, even if the mean heart rate
was faster in the LQT1 group.
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influence of epinephrine in prolonging the mean cQTe,
maximum cQTe and minimum cQTe values, as well as in
increasing the mean cTp-e and cQTe-D values. The differ-
ences in all variables with epinephrine with oral propranolol
were not significantly different between the two groups.
DISCUSSION
The major findings of this study were: 1) propranolol under
normal sympathetic tone produces a greater decrease in
TDR in LQT1 than in LQT2 syndrome but does not
change the SDR in either the LQT1 or LQT2 syndrome;
and 2) propranolol completely suppresses the influence of
sympathetic stimulation in increasing TDR and SDR and
prolonging the QT interval in both the LQT1 and LQT2
syndromes.
Effects of beta-blockade when sympathetic tone is normal.
Although beta-blockers have been shown to be effective in
preventing cardiac events in patients with LQTS, especially
the LQT1 form (7,17), Linker et al. (18) reported that
beta-blockade modified neither the corrected QT (cQT)
interval nor cQT dispersion on the 12-lead ECG. Priori et
al. (19) have reported that patients with LQTS who
responded to beta-blockers showed less cQT dispersion
than did non-responders. To the best of our knowledge, this
is the first study to compare the effect of beta-blockade on
both TDR and SDR between the LQT1 and LQT2
syndromes. The data suggest that beta-blockade under
normal sympathetic tone decreases the mean cTp-e value, as
an index of TDR, more in LQT1 than in LQT2 syndrome,
which likely explains the superior effectiveness of beta-
blockers in LQT1 versus LQT2 syndrome. Experimental
studies using arterially perfused wedge preparations have
demonstrated that therapeutic concentrations of proprano-
lol had little or no effect on the Q-Tend interval, action
potential duration (APD) of the three cell types or TDR
(10,11), in contrast to the clinical data of the present study.
In the clinic, patients with either LQT1 or LQT2 were
exposed to considerable sympathetic tone even under base-
line conditions, which is expected to shorten the APD more
in epicardial cells (larger IKs) than in M cells (weaker IKs),
resulting in an increase in TDR, especially in the LQT1
group. Therefore, beta-blockers reverse the influence of
normal sympathetic tone and are expected to prolong the
epicardial APD and to decrease TDR, especially in the
LQT1 patients.
The cQTe-D, as an index of SDR, was not changed with
beta-blockade alone in both the LQT1 and LQT2 syn-
dromes, even though 87-lead ECGs were simultaneously
Figure 4. Differences before and after epinephrine at the baseline condition and with oral propranolol in the mean cQTe (A), mean cQTp (B), mean cTp-e
(C), maximum cQTe (D), minimum cQTe (E) and cQTe-D (F) in 11 LQT1 patients (open circles) and 11 LQT2 patients (solid circles). The differences
in the mean cQTe, mean cTp-e, maximum cQTe and cQTe-D values with epinephrine at the baseline condition were significantly greater in the LQT1
group than in the LQT2 group. In both groups, propranolol completely suppressed the influence of epinephrine, and the differences in all variables with
epinephrine plus oral propranolol were not significantly different between the two groups.
1989JACC Vol. 39, No. 12, 2002 Shimizu et al.
June 19, 2002:1984–91 Beta-Blockade on Dispersion in LQTS
recorded. Our data are consistent with the results of Linker
et al. (18); however, they may be explained by a recent,
elegant study using computer simulation, conducted by
Burnes et al. (20), who suggested that regional heterogene-
ity of repolarization was not reflected in QT dispersion
recorded from the body-surface, 12- or 64-lead ECG.
Effects of beta-blockade during sympathetic stimulation.
Physical exercise and strong emotion have long been known
to precipitate syncope and sudden cardiac death in patients
with congenital LQTS (1–3). Among three forms of con-
genital LQTS, the LQT1 form has proved to be more
sensitive to sympathetic stimulation, compared with either
LQT2 or LQT3, both clinically (7–9,21) and experimen-
tally (10,11). In the clinic, QT dispersion has been reported
by Sun et al. (22) to be markedly increased with epinephrine
in patients with LQTS. In our present study and previous
studies using 87-lead, body-surface ECG, augmentation of
sympathetic stimulation with epinephrine infusion pro-
duced a greater increase in both TDR (mean cTp-e) and
SDR (cQTe-D) in LQT1 versus LQT2 syndrome (12),
supporting the fact that the LQT1 patients are more at risk
when they are under strong sympathetic stimulation. In the
present study, oral propranolol completely suppressed epi-
nephrine’s influence on increasing TDR and SDR in both
the LQT1 and LQT2 syndromes. This finding was consis-
tent with the effects of propranolol in experimental models
of the LQT1 and LQT2 syndromes (10,11). Increases in
both TDR and SDR are thought to provide a substrate for
reentrant arrhythmias, such as torsade de pointes in con-
genital LQTS (10,11,13–15,23–25). Therefore, our data
suggest that beta-blockers at least prevent the substrate for
reentry from being arrhythmogenic during augmentation of
sympathetic stimulation, equally in the LQT1 and LQT2
syndromes. Schwartz et al. (7) have recently demonstrated
that beta-blockers were more effective in suppressing the
recurrence of cardiac events in LQT1 versus LQT2 syndrome
(81% vs. 59%). Taken together with our data, other predispos-
ing factors such as hypokalemia or bradycardia, as well as
triggering factors such as early afterdepolarization-mediated
extrasystole, in addition to augmented sympathetic stimula-
tion, may play a more significant role in the development of
torsade de pointes in patients with LQT2 syndrome.
Study limitations. Although recent experimental studies
using arterially perfused wedge preparations have shown
that the transmural voltage gradient across the ventricular
wall has an important contribution to the cellular basis of
normal and abnormal T-waves (10,11,13–15), there is not
enough evidence to claim that this observation can be
transferred to the clinical ECG. Therefore, great caution
must be taken in interpreting the data of the present study.
Because 87-lead, body-surface mapping is not widely
available, we measured repolarization variables by using six
precordial leads. As shown in the Figures 1 and 2, the
results were basically similar to those obtained from 87 leads
(data not shown).Ta
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